Ex vivo lumbar and post mortem ventricular cerebrospinal fluid substance P-immunoreactivity in Alzheimer's disease patients

Neuroscience Letters

Volumn 299, Issue 1-2, 2001, Pages 117-120

  Rösler, Norbert ^a   Wichart, Ildiko ^a   Jellinger, Kurt A ^a  

^a INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

Alzheimer's disease; Biomarker; Cerebrospinal fluid; Diagnosis; Enzyme linked immunosorbent assay; Substance P

Indexed keywords

SUBSTANCE P;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CADAVER; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

AGE OF ONSET; AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; POSTMORTEM CHANGES; SPINAL PUNCTURE; SUBSTANCE P;

EID: 0035895703     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(01)01514-2     Document Type: Article

References (18)

1. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients
2. Neuropathological stageing of Alzheimer-related changes
3. Somatostatin-like immunoreactivity and substance P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus
4. Cerebrospinal fluid immunoreactive substance P and somatostatin in neurological patients with peripheral and spinal cord disease
5. 'Mini mental state': A practical method for grading the cognitive state of patients for the clinician
6. Interleukin-6 secretion from human astrocytoma cells induced by substance P
7. Neurochemical abnormalities in Alzheimer's disease and Parkinson's disease - A comparative review
8. Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients
9. Structural basis of dementia in neurodegenerative disorders
10. An in vivo model for the neurodegenerative effects of β amyloid and protection by substance P
11. Substance P and neuropsychiatric disorders: An overview
12. 2-microglobulin with neuropeptides in cerebrospinal fluid of patients with dementia of the Alzheimer type
13. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
14. Substance P in human cerebrospinal fluid: Reductions in peripheral neuropathy and autonomic dysfunction
15. Central nervous system IgG synthesis rates in Alzheimer disease: Possible differences in early-onset and late-onset subgroups
16. The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease. A clinicopathologic study of 57 cases
17. Neuropeptide changes in dementia: Pathogenic implications and diagnostic value
18. Neurotrophic and neurotoxic effects of amyloid β protein: Reversal by tachykinin neuropeptides